Internal Medicine

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

Therapeutic candidate Sparsentan could expand treatment options for 2 rare kidney diseases. Dr. Jula Inrig expands on the potential for the FSGs patient population.

Patients with psoriasis in high-impact areas may benefit from either of 2 available dosing regimens of the biologic.

Sleep Medicine Expert Daniel Gottlieb, MD, MPH, details a response to the USPSTF screening recommendations for obstructive sleep apnea in a primary care setting.

US Prevention Services Task Force (USPSTF) announces that after reviewing the clinical utility of obstructive sleep apnea screening tools in a primary care setting, there's insufficient evidence to determine the balance between benefit and harm.

David R. Lally, MD, reviews the duration and patient demographic data of the investigative drug.

Nonprofit organizations combined efforts to plan a meeting to inform and educate the FDA and key stakeholders about the experience of caregivers and patients with Phelan-McDermid syndrome (PMS).

A retrospective comparative trial showed that agents including bevacizumab, ranibizumab and aflibercept are linked to similar likelihood of RPE tears.

Dr. Jula Inrig highlights the key data presented at ASN Kidney Week on investigational candidate Sparsentan for IgA nephropathy.

Investigators evaluated how the risk of kidney failure and death affects US veterans with chronic kidney disease (CKD) in research presented at Kidney Week 2022 ASN Annual Meeting.

New research presented at Kidney Week 2022 ASN Annual Meeting, demonstrates an association between albuminuria and risk of cognitive problems.

An analysis of over-the-counter products show not all AMD-targeting supplements match the recommended dosage from the National Institutes of Health.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.

Aside from the inability to fulfill the site inspection, there was no other reason for the FDA deferral. The approval of the combination drug candidate's 2 components are still expected.

Depressive disorders are often accompanied by low levels of resilience and research indicates that targeting insomnia symptoms could address the severity of these psychiatric disorders.

Yale dermatologist Christopher Bunick, MD, PhD, discusses the recurring issue with increased levels of the carcinogen found in self-care and cosmetic products.

Iptacopan has the potential to address an unmet need in PNH by significantly increasing hemoglobin levels in patients who remain anemic, fatigued and dependent on blood transfusions after anti-C5 treatment.

New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.

The sixth indication for the JAK inhbitior from AbbVie makes it the first in class approved for both nr-axSpA and ankylosing spondylitis.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.